Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Fineline Cube May 8, 2026
Company Drug

Jiangsu Hengrui Pharmaceuticals Advances HRS-5965 with NMPA Clinical Trial Approval for Glomerular Diseases

Fineline Cube May 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...

Company

Organon’s Q1 2024 Revenues Rise 7% YOY, Women’s Health and Biosimilars Lead the Way

Fineline Cube May 9, 2024

Organon (NYSE: OGN), a leading women’s health specialist, announced a 7% year-on-year increase in revenues...

Company Drug

Innovent Biologics’ Mazdutide Shows Superiority in Type 2 Diabetes Phase III Trial

Fineline Cube May 9, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Medical Device

Blue Sail Medical’s New Catheter Receives NMPA Approval for Complex Coronary Lesion Treatment

Fineline Cube May 9, 2024

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has received marketing approval from the National...

Company Drug

Abbisko and Allist Pharmaceuticals Initiate Phase II Trial for NSCLC Drug Combination

Fineline Cube May 9, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256) and Allist Pharmaceuticals Co., Ltd have announced the upcoming...

Company R&D

Profluent’s Neural Network Model Designs High-Efficiency CRISPR Gene-Editing System

Fineline Cube May 8, 2024

Biotechnology company Profluent has announced a significant advancement in the field of gene editing with...

Company Drug

Boehringer Ingelheim’s Anti-Sema3A BI 764524 Shows Promise in Diabetic Macular Ischemia Trial

Fineline Cube May 8, 2024

Boehringer Ingelheim (BI) has announced the publication of results from a Phase I/IIa clinical trial...

Company Drug

Pfizer Pauses Dosing in DMD Gene Therapy Trial Following Participant’s Sudden Death

Fineline Cube May 8, 2024

This week, Pfizer Inc. (NYSE: PFE) announced the unfortunate sudden death of a participant in...

Company Deals

Tonghua Dongbao Pharmaceuticals Inks Licensing Deal for Semaglutide in China

Fineline Cube May 8, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a licensing agreement...

Company Drug

J&J’s Erleada Plus ADT Shows 0% Biochemical Recurrence Rate in High-Risk Prostate Cancer Trial

Fineline Cube May 8, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Phase II clinical trial for...

Company Deals

China’s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea

Fineline Cube May 8, 2024

China’s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South...

Company

Siemens Healthineers Reports 3% YOY Growth in Q2 2024 Fiscal Report Amidst Challenging Comparison

Fineline Cube May 8, 2024

Germany’s medical technology leader Siemens Healthineers AG (ETR: SHL) has reported its financial results for...

Company

AstraZeneca Hong Kong Launches ‘HRDetect’ Program to Offer Free Genetic Testing for Cancer Patients

Fineline Cube May 8, 2024

AstraZeneca (AZ, NASDAQ: AZN) Hong Kong has announced a partnership with Inocras Hong Kong Ltd...

Company Deals

Siemens Healthineers AG Forges Expanded Partnership with Xi’an Daixing Hospital

Fineline Cube May 8, 2024

Germany’s Siemens Healthineers AG (ETR: SHL) has entered into an eight-year value partnership with Xi’an...

Company Drug

Everest Medicines’ Velsipity for UC Receives First Asian Approval in Macau

Fineline Cube May 8, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the regulatory authority in...

Company Drug

Wanbangde Pharmaceutical’s Huperzine A Earns FDA Rare Pediatric Disease Designation for HIE Treatment

Fineline Cube May 8, 2024

China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced that its subsidiary, Wanbangde...

Company Medical Device

Andon Health’s Triplex Virus Test Kit Receives US FDA Emergency Use Authorization

Fineline Cube May 8, 2024

Andon Health Co., Ltd (SHE: 002432), a leading healthcare company based in China, has announced...

Company Deals

Citi Pharma Ltd and Hangzhou Newsea Technology Form JV to Boost API Production

Fineline Cube May 8, 2024

Pakistan-based pharmaceutical company Citi Pharma Ltd is entering into a joint venture (JV) agreement with...

Company Medical Device

Medtronic’s RDN System Symplicity Spyral Earns First-Ever NMPA Approval

Fineline Cube May 8, 2024

Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced that its Symplicity Spyral renal...

Company Policy / Regulatory

Xi and Macron Discuss Enhanced Market Access for Foreign Investors, Focus on Life Sciences

Fineline Cube May 8, 2024

This week, talks between China’s President Xi Jinping and France’s President Emmanuel Macron in France...

Posts pagination

1 … 360 361 362 … 661

Recent updates

  • Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength
  • Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion
  • Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation
  • Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment
  • Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength

Company

Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion

Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.